The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | Treatment approaches for patients with R/R AML and the importance of preventing relapse
Alessandro Isidori, MD, PhD, Marche Nord Hospital, Pesaro, Italy, discusses treatment approaches for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), highlighting the importance of preventing relapse with maintenance therapy. Dr Isidori further discusses the value of using genetic tests to identify mutations present at relapse, and directly targeting these mutations with agents such as ivosidenib, enasidenib, gilterinib, and quizartinib. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
